| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -4.61 M USD | -5.81 M USD | -4.69 M USD | -3.02 M USD | -1.25 M USD | -499551 USD | -909476 USD | -1.01 M USD | -542703 USD | -520808 USD | -366414 USD | — |
| Depreciation & Amortization | 4.78 M USD | 4.80 M USD | 4.87 M USD | 4.83 M USD | 2.04 M USD | 14698 USD | 22241 USD | 56194 USD | 39990 USD | 25956 USD | 19772 USD | — |
| Stock-Based Compensation | 1.73 M USD | 3.54 M USD | 1.11 M USD | 6.42 M USD | 160978 USD | 150440 USD | 0 USD | 100366 USD | 106250 USD | — | — | — |
| Capital Expenditures | 34561 USD | 21331 USD | 92984 USD | 633823 USD | 143792 USD | 0 USD | 1638 USD | 4908 USD | — | 47686 USD | 7081 USD | — |
| Cash Flow from Investing | -2223 USD | -125292 USD | -101525 USD | -630178 USD | -180517 USD | -7243 USD | -13107 USD | -7277 USD | -49096 USD | -148330 USD | -11578 USD | — |
| Cash Flow from Financing | 1.01 M USD | 8.03 M USD | 4.92 M USD | 3.83 M USD | 3.15 M USD | 120000 USD | 54968 USD | 254979 USD | 2.44 M USD | 782125 USD | 80574 USD | — |
| Dividends Paid | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock Buybacks | — | — | — | — | — | — | — | — | — | — | — | — |
| Free Cash Flow | -4.65 M USD | -5.83 M USD | -4.79 M USD | -3.66 M USD | -1.39 M USD | -499551 USD | -911114 USD | -1.01 M USD | — | -568494 USD | -373495 USD | — |
Ainos Inc. is a dual-platform AI and biotech company focused on pioneering smelltech and immune therapeutics. Its smelltech platform, powered by AI Nose and a smell language model (SLM), digitizes scents into Smell ID, a machine-readable data format that enables intelligent sensing in robotics, smart factories, and healthcare applications. The company develops VELDONA®, a low-dose oral interferon therapy targeting rare, autoimmune, and infectious diseases, with active clinical programs in areas such as HIV-related oral warts, primary Sjögren’s syndrome, and feline chronic gingivostomatitis. Ainos Inc. also leverages proprietary sensor array technologies to advance healthcare AI and offers point-of-care testing devices, including antigen rapid test kits. These innovations position Ainos Inc. at the intersection of AI-driven diagnostics, scent digitization, and therapeutic solutions, serving medtech needs in diverse healthcare and technology sectors. Incorporated in 1984 and headquartered in the United States, Ainos Inc. continues to redefine machine perception through its integrated AI and biotech capabilities.